Side-by-side facts
Probiotic Products Compared: Strains, CFU & Evidence
Compare probiotic products by strain or formulation identity, viable count, storage, indication-specific evidence and the main limitation of each formula.
Key differences
Strain or formulation identity and indication-specific evidence matter more than headline CFU count alone. Medical-food evidence should also remain tied to the population and use that were actually studied.
| Product | Relevant for | Research status | Main tradeoff | Last checked |
|---|---|---|---|---|
| Align 24/7 Digestive Support | People comparing probiotics by exact strain rather than CFU marketing | Strain clinical evidence mixed | Far better strain transparency than generic blends, but benefits are indication-, population- and dose-specific. | 2026-08-11 |
| Bio-K+ Advanced Bowel Support Probiotic Capsules | People comparing probiotics with named strains and a direct professional-guideline connection | Evidence mapped | The product names its strains and guarantees CFU through expiration. Two strains appear in AGA guidance, while a later cluster-randomized hospital trial of the three-strain capsule did not significantly reduce hospital-acquired C. difficile infection. | 2026-08-12 |
| Culturelle Digestive Daily Probiotic Capsules | People who want a named probiotic strain and expiration-date CFU guarantee | Strain clinical evidence with negative use | Strong strain identity and viability documentation, but no probiotic strain is universally effective across conditions. | 2026-08-11 |
| Florastor Dual Action | Adults comparing a clearly identified S. boulardii strain | Evidence mapped | The strain is disclosed and the product is stored at room temperature; usefulness remains indication-specific, and serious-infection risk matters in vulnerable patients. | 2026-08-12 |
| Ther-Biotic ABx Support | People whose clinician specifically selected this product during antibiotic treatment | Evidence mapped | Convenient antibiotic-focused positioning, but the evidence bridge from guideline-supported strains to this exact blend is incomplete. | 2026-08-12 |
| Ther-Biotic Complete | People already using this formula with a clinician who values its broad species mix and allergen profile | Evidence mapped | The label gives species-level quantities but not strain designations on the current US page, limiting strain-specific trial matching. | 2026-08-12 |
| Ther-Biotic Saccharomyces boulardii | People whose clinician specifically wants this Klaire/SFI product and understands the species-versus-strain limitation | Evidence mapped | Simple formula and clear CFU amount, but much weaker trial traceability than a strain-identified S. boulardii product. | 2026-08-12 |
| Visbiome GI Care | People with recurrent antibiotic-responsive pouchitis discussing prevention with their gastroenterologist | Evidence mapped | Formulation identity and pouchitis-guideline relevance are documented; refrigeration, high potency and the narrow medical-use evidence make it unsuitable as a generic wellness default. | 2026-08-12 |
Compare identity before CFU count
Two products can list the same species while containing different strains. When a study or guideline names a strain or defined formulation, that identity should remain attached to the evidence.
CFU count is useful only after organism identity, storage or shelf-life conditions and intended use are clear.
Keep indications separate
Evidence for prevention of a specific antibiotic-associated outcome, recurrent pouchitis or another defined use does not establish a generic benefit for IBS, bloating or everyday wellness.
The table includes both ordinary probiotic supplements and probiotic medical foods so formulation-level evidence can be compared without erasing differences in intended use.
Use the product fact sheet for source detail
Each product page separates manufacturer labeling from professional guidance, trials and other external evidence. Missing strain codes or missing product-specific trials remain visible limitations.
Read Probiotics: Strains, Products & Evidence by Condition for the condition-specific evidence discussion, including the narrow recurrent-pouchitis context for the De Simone Formulation.
Source trail
Primary documents and supporting evidence
- Probiotics — Consumer Fact SheetNIH Office of Dietary Supplements · Government health · retrieved 2026-08-12
- Role of probiotics in the management of gastrointestinal disordersAmerican Gastroenterological Association · Clinical guideline · retrieved 2026-08-12
- IBS Treatment — ProbioticsAmerican College of Gastroenterology · Professional health · retrieved 2026-08-12
- AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch DisordersAmerican Gastroenterological Association / Gastroenterology · Clinical guideline · retrieved 2026-08-12